

**IBTROZI
(taletrectinib)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
 - a. ROS1-positive

AND ALL of the following:

- a. Prescriber agrees to monitor uric acid levels and liver function tests (LFTs) including bilirubin
- b. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ibtrozi and for 3 weeks after the last dose
- c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ibtrozi and for 3 weeks after the last dose

Prior - Approval Limits

Quantity 600 mg per day

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)

AND ALL of the following:



**BlueCross
BlueShield**

Federal Employee Program.

**IBTROZI
(taletrectinib)**

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor uric acid levels and liver function tests (LFTs) including bilirubin
- c. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ibtrozi and for 3 weeks after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Ibtrozi and for 3 weeks after the last dose

Prior - Approval *Renewal* Limits

Same as above